Details
| Original language | English |
|---|---|
| Pages (from-to) | 719-729 |
| Number of pages | 11 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 167 |
| Issue number | 3 |
| Publication status | Published - Feb 2018 |
| Externally published | Yes |
Abstract
Purpose In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. Methods Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vig-orous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms. Results The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred. Conclusions An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.
Keywords
- Breast cancer, Cardiotoxicity, Doxorubicin, Exercise, Treatment symptoms
ASJC Scopus subject areas
- Medicine(all)
- Oncology
- Biochemistry, Genetics and Molecular Biology(all)
- Cancer Research
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Breast Cancer Research and Treatment, Vol. 167, No. 3, 02.2018, p. 719-729.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms
T2 - a RCT
AU - Kirkham, Amy A.
AU - Eves, Neil D.
AU - Shave, Rob E.
AU - Bland, Kelcey A.
AU - Bovard, Joshua
AU - Gelmon, Karen A.
AU - Virani, Sean A.
AU - McKenzie, Don C.
AU - Stöhr, Eric J.
AU - Waburton, Darren E.R.
AU - Campbell, Kristin L.
N1 - Funding Information: Financial support This work was supported by an Anita Cochrane Memorial Fund Award from the British Columbia Cancer Foundation. AK was supported by the Canadian Institutes of Health Research. We also acknowledge the support of GE Healthcare.
PY - 2018/2
Y1 - 2018/2
N2 - Purpose In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. Methods Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vig-orous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms. Results The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred. Conclusions An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.
AB - Purpose In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. Methods Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vig-orous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms. Results The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred. Conclusions An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.
KW - Breast cancer
KW - Cardiotoxicity
KW - Doxorubicin
KW - Exercise
KW - Treatment symptoms
UR - http://www.scopus.com/inward/record.url?scp=85033496718&partnerID=8YFLogxK
U2 - 10.1007/s10549-017-4554-4
DO - 10.1007/s10549-017-4554-4
M3 - Article
C2 - 29110150
AN - SCOPUS:85033496718
VL - 167
SP - 719
EP - 729
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 3
ER -